Validation of DNA Methylation Markers for Universal and Site-specific Guided Cancer Detection, VANGUARD Study

Summary

This study explores the potential value of a new blood test approach for early detection of cancer.

Eligibility

Inclusion Criteria:

* Aim 1 Tissue

  * Cases:

    * Patient has a biopsy confirmed diagnosis of target histology
    * Tissue samples from synchronous or metachronous primary cancers may be used as long as they are clearly of a different target organ.
    * Tumors from patients with an underlying genetic disorder pre-disposing to cancer may be included as long as they are stratified from those without
  * Controls:

    * Patient does not have the diagnosis of target histology
* Aim 2 Blood

  * Cases:

    * Patient has a biopsy confirmed diagnosis of target histology or radiographic criteria that are unequivocal for diagnosis (example, meets radiographic criteria for hepatocellular carcinoma)
  * Controls:

    * Patient does not have a diagnosis of the target histology
* Aim 3 Urine

  * Cases:

    * Patient has a biopsy confirmed diagnosis of target histology or radiographic criteria that are unequivocal for diagnosis (example, meets radiographic criteria for hepatocellular carcinoma)
  * Controls:

    * Patient does not have a diagnosis of the target histology

Exclusion Criteria:

* Aim 1 Tissue

  * Cases and Controls:

    * Patient has had any transplants prior to tissue collection
    * Patient has received chemotherapy class drugs within 5 years prior to tissue collection
  * Cases:

    * Patient has had radiation to the current target lesion prior to tissue collection
    * Patient has multi-centric/multi-focal breast cancer with differing genetic profiles (ER/HER2/PR status differ; if multiple masses are present and not all are tested then exclude patient)
    * Patient has bilateral breast cancer/Ductal carcinoma in situ (DCIS)
* Aim 2 Blood

  * Cases and Controls:

    * Patient has known cancer outside of the target cancer 5 years prior to blood collection (not including basal cell or squamous cell skin cancers)
    * Patient has received chemotherapy class drugs in the 5 years prior to blood collection
    * Patient has had any prior radiation therapy to the target lesion prior to blood collection
    * Patient has had a biopsy to the target organ and/or lesion within 3 days before blood collection
  * Cases:

    * Patient has had an intervention to completely remove current target pathology
    * The current target pathology is a recurrence
    * Patient has multi-centric/multi-focal breast cancer with differing genetic profiles (ER/HER2/PR status differ; if multiple masses are present and not all are tested then exclude patient)
    * Patient has bilateral breast cancer/DCIS
* Aim 3 Urine

  * Patient has known cancer outside of the target cancer 5 years prior to urine collection (not including basal cell or squamous cell skin cancers)
  * Patient has received chemotherapy class drugs in the 5 years prior to urine collection
  * Patient has had any prior radiation therapy to the target lesion prior to urine collection
  * Patient has had a biopsy to the target organ and/or lesion within 3 days before urine collection
  * The current target pathology is a recurrence
  * Patient has chronic indwelling urinary catheter
  * Patient has had a urinary tract infection within the 14 days prior to sample collection
  * If patient does not have a primary bladder, ureter or urethral cancer, patient has a history of bladder ureter, or urethral cancer
  * Cases:

    * Patient has had an intervention to completely remove current target pathology
    * The current target pathology is a recurrence
    * Patient has multi-centric/multi-focal breast cancer with differing genetic profiles \[estrogen receptor (ER)/human epidermal growth factor receptor 2 (HER2)/progesterone receptor (PR)\] status differ; if multiple masses are present and not all are tested then exclude patient)
    * Patient has bilateral breast cancer/DCIS

Conditions3

Locations1 site

Browse More Trials